NIMENRIX (Meningococcal Group A, C, W-135 and Y conjugate vaccine) - Meningococcal vaccines

Opinions on drugs - Posted on Jul 26 2024

Reason for request

Modification of the listing conditions

Summary of opinion

Favourable opinion for maintenance of reimbursement in the active immunisation of individuals against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y, in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024.

Clinical Benefit

Substantial

The Committee deems that updating of the vaccine strategy in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical benefit, which remains substantial in the active immunisation of individuals against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y.

Clinical Added Value

major

Updating of the vaccine strategy in accordance with the current HAS recommendations of 7 March 2024 and 27 June 2024 is not of a nature to modify the clinical added value in the active immunisation of individuals against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 and Y:

major clinical added value (CAV I) in infants aged from 6 weeks to 12 months, according to the opinion of 06/10/21,
major clinical added value (CAV I) in infants aged from 12 to 23 months and minor clinical added value (CAV V) in children aged 2 years or more, adolescents and adults, according to the listing opinion of 05/12/2012).

no clinical added value